MicroRNA from stem cells could be used to treat babies while still in the womb

29 Apr 2021, 3:11 p.m.

Paolo de Coppi

Using tiny liquid ‘bubbles’ of microRNAs from stem cells, a team of researchers from Great Ormond Street Hospital (GOSH) and The Hospital for Sick Children (SickKids, in Toronto has regenerated under-developed lungs in rats while still in the womb.

As babies develop in the womb, the growth of their lungs is a critical part of development, and any disruptions can lead to under-developed lungs, leading to disability or even stillbirth. Known as ‘pulmonary hypoplasia’, this condition usually occurs alongside other medical conditions or due to other malformations, like when the diaphragm fails to properly close during development. Infants born with the severest cases only have a survival rate of 60% and those who do survive face a lifetime of complications. Treatment options can involve surgery even before the baby is born but irreparable damage is often done to the lungs.

Now, scientists and doctors from two of the world’s leading children’s hospitals have come together to take advantage of the regenerative properties of stem cells isolated from amniotic fluid. These cells produce tiny liquid ‘bubbles’, called vesicles, containing microRNAs that boost the genes that support the developing lung. The team found that using microRNAs isolated from a donor’s amniotic fluid stimulated lung growth, proper lung structure, and the creation of lung cells in the laboratory and in animal models of pulmonary hypoplasia.

This research was published in Science Translational Medicine

Professor Paolo De Coppi (pictured), Consultant Paediatric Surgeon at GOSH and Head of Stem Cells and Regenerative Medicine at GOS UCL ICH said: "Stem cells are well-known to have anti-inflammatory effects, but this is the first time we have shown that it is the vesicles – containing microRNA – that are capable of this regenerative effect. By using a donor for the stem cells, we are able to create something you can use ‘off-the-shelf’ and by using the vesicles and not the whole stem cells, we remove the risk of potentially cancerous side effects.”

Professor Augusto Zani, Neonatal and Paediatric Surgeon, Division of General and Thoracic Surgery, and Scientist in the Developmental and Stem Cell Biology program at SickKids said: “We have built on the stem cell research developed by collaborators at GOSH and applied it to a whole new disease – it’s very exciting. Our next steps will be to show that this works in humans but we are hopeful from preliminary data that this will be successful. The long-term vision is to get this treatment into a clinical trial for babies born with severe malformations of the diaphragm.”

All research at Great Ormond Street Hospital is supported by the NIHR GOSH BRC.

Euro group to boost access to life-saving gene therapies

A new Europe-wide academic group has been launched today to tackle the growing economic hurdles that are preventing new life-saving gene therapies getting to the children who need them the most.

New trial for innovative Haemophilia treatment begins at GOSH

Researchers at Great Ormond Street Hospital (GOSH) have begun a new clinical trial for an innovative haemophilia treatment for boys under 12.

Our journey to build a ‘Hospital Without Walls’

Every day, we develop innovations in care, enabling us to be one of Europe's most digitally able hospitals. Because of this strategy, we were able to use Zoom for patient video consultations just eight days after the Covid-19 pandemic began.

Investigating the rise in hepatitis in children

Due to our world-leading expertise in genomics, we've teamed up with the UK Health Security Agency (UKHSA) to understand why more children than normal are being diagnosed with liver infections (hepatitis)...